Assess the in vitro efficacy of nanoparticles as carrier's magnetic liposomal paclitaxel on ovarian cancer

Aim and By expanding knowledge about this disease, many progress and developments for curing this disease have been performed. The toxic effects of chemotherapy drugs still pose a treatment problem, because of their pharmokinetic changes and careful targeting as one of the promising strategies are proposed in cancer and incurable disease treatments. Magnetic Nano particles are essential and vital in drug delivery, since their natural magnet, facilitates targeting and other things.
Magnetic nanoparticles were prepared by co-precipitation method. Then, by using discharge metod, liposomal nanoparticle’s film and magnetic nanoparticle’s film, containing paclitaxel were prepared. Also drug releasing and capsulation amount and drug loading, size and potential zeta of magnetized liposomal Nanoparticles were mentioned. The cytotoxicity of nanoparticles containing the drug was studied by using MTT assay on cell of ovarian cancer A2780CP.
. The size of magnetic liposome nanoparticles containing the drug and the liposomes containing the drug, respectively, 251 and 198 nm were estimated. And zeta potential of these particles, respectively, -20 and -19 (mv) was calculated. Also the magnetic liposome carrier had slow-release and longer half-life than liposome.
Encapsulation efficiency of carriers, magnetic liposome and liposome of paclitaxel respectively 97and 96 percent were. Release studies show, Continuous and controlled drug release from the magnetic liposome nanoparticles. MTT results showed that, magnetic liposome had a higher cytotoxicity than liposomal nanoparticles against cells A2780CP imposed.
The results of the study showed that, magnetic liposome nanoparticles were more appropriate carrier than liposome nanoparticles for drug delivery of paclitaxel in ovarian cancer cells are A2780CP.